Sentinel node biopsy in malignant melanoma: Swedish experiences 1997–2005

Mattsson, Jan; Bergkvist, Leif; Abdiu, Avni; Low, Janina Francisca Aili; Naredi, Peter; Ullberg, Karin; Garpered, Ulf; Håkansson, Annika; Ingvar, Christian

doi:10.1080/02841860701785533

Cited by 21 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our series, SLNB gave negative results in 73.1% (503 of 688) of cases, in agreement with previously reported data 18–20 . Despite negative SLNB, PD occurred in 22.7% of those patients.…”

Section: Discussionsupporting

confidence: 93%

Disease progression in melanoma patients with negative sentinel lymph node: does false‐negative specimens entirely account for this phenomenon?

Savoia

Fava

Caliendo

et al. 2011

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Disease progression in melanoma patients with negative sentinel lymph node: does false‐negative specimens entirely account for this phenomenon?

Savoia

Fava

Caliendo

et al. 2011

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…This variation might be attributed to the limited number of patients with stage III disease at initial diagnosis and the fact that SLN biopsy was not performed systemically during the entire study period. Although the SLN technique was introduced in Sweden in 1997, implementation has been slow and recommendations regarding when SLN biopsy is indicated were adjusted in 2007 . Proportion of stage III and IV patients decreased over the study period but remained higher than previously reported figures, which can be due to both altered disease characteristics and treatment considerations.…”

Section: Discussionmentioning

confidence: 92%

Epidemiology of cutaneous melanoma in Sweden—Stage‐specific survival and rate of recurrence

Rockberg¹,

Amelio

Taylor

et al. 2016

Intl Journal of Cancer

View full text Add to dashboard Cite

Cutaneous malignant melanoma (CMM) incidence is increasing globally, making a thorough understanding of the disease and its outcomes essential for optimizing care even more urgent. In this population-based, retrospective study, we investigated stage-specific survival and recurrence/progression rates of CMM among patients diagnosed in Stockholm County Council during 2005-2012, before the wide introduction of targeted therapy. A total of 3,554 CMM patients from the Stockholm Melanoma Register were included. Information on comorbidities, progression, death, and treatments was obtained from nationwide registers and hospital electronic medical records. Unadjusted 5-year survival varied from 91.4% for stage I to 24.6% for stage IV patients. Stage, age and gender were predictors of survival, with gender an independent predictor of survival for stages IA and IIA. 74.6% of patients remained recurrence/progression-free during follow-up, with 5-year recurrence/progression-free survival rates varying from 85.3% to 12.9% among stages I and IV patients, respectively. In addition to stage, male gender, and age, circulatory system comorbidities increased the risk for recurrence/progression. No statistically significant differences in progression rate for operated and non-operated patients could be detected, possibly due to high rate (98.9%) of surgery. Our estimates of survival and recurrence rates are consistent with historical and global expectations and can serve as a baseline to gauge population-level improvements with use of novel melanoma treatments.

show abstract

“…Our result is in accordance with several other studies. Recently, Mattsson et al reported a sentinel-positivity rate of 17% in patients with H&N melanoma versus 21% and 23% in truncal and leg melanomas, respectively [20]. Leong et al have published their results of the multi-institutional SLN Working Group on 629 H&N melanoma patients who underwent SNB.…”

Section: Discussionmentioning

confidence: 99%

Head and neck cutaneous melanoma: A retrospective observational study on 146 patients

et al. 2009

View full text Add to dashboard Cite

Sentinel node biopsy in malignant melanoma: Swedish experiences 1997–2005

Cited by 21 publications

References 22 publications

Disease progression in melanoma patients with negative sentinel lymph node: does false‐negative specimens entirely account for this phenomenon?

Disease progression in melanoma patients with negative sentinel lymph node: does false‐negative specimens entirely account for this phenomenon?

Epidemiology of cutaneous melanoma in Sweden—Stage‐specific survival and rate of recurrence

Head and neck cutaneous melanoma: A retrospective observational study on 146 patients

Contact Info

Product

Resources

About